| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | The Southwest Hospital of AMU | Leukemia; Leukemia, Myeloid | Details | |
| CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Myeloid | Details | |
| CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech) | BAH244; BAH-244 | Phase 2 Clinical | Essen Biotech | Leukemia, Myeloid, Acute | Details |
| AZD-9829 | AZD9829; AZD-9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Diseases; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University, Xuzhou Medical University (Xzmu) | Leukemia, Myeloid, Acute | Details | |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| Mipletamig | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
| Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 1 Clinical | Macrogenics Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Neoplasms, Plasma Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| UCART-123 | UCART-123; UCART-123v1.2 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
| Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
| MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | City Of Hope National Medical Center, Mustang Bio Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hodgkin Disease; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms | Details |
| AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms | Details |
| VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD123 LV redirected T cells Therapy (Childrens Hospital of Philadelphia) | CART123 | Phase 1 Clinical | Childrens Hospital of Philadelphia | Leukemia, Myeloid, Acute | Details |
| JY-017 | JY017; JY-017 | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Leukemia, Myeloid, Acute | Details |
| ACLX-004 | ACLX-004 | Phase 1 Clinical | Arcellx Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital) | Phase 1 Clinical | Pla General Hospital | Leukemia, Myeloid, Acute | Details | |
| Autologous CAR123 T lymphocytes cell tharapy(Institute of Hematology and Blood Transfusion, Czech Republic) | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD123 CAR NK cells therapy(Chongqing Precision Biotechnology) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Neoplasms, Plasma Cell | Details | |
| RJK-RT2831 | RJK-RT2831; RJKRT2831; RT-2831; RT2831 | Phase 1 Clinical | Nanjing RegeneCore Biotech Co Ltd | Hematologic Neoplasms | Details |
| CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
| CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Blastic Plasmacytoid Dendritic Cell Neoplasm; Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| LAVA-1266 | LAVA1266; LAVA-1266 | Phase 1 Clinical | Lava Therapeutics NV | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
| Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
| BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
| SAR-443579 | SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101 | Phase 1 Clinical | Sanofi | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms | Details |
| IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis | Details |




